Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BioHarvest Sciences (BHST) Stock Price & Analysis

BHST Stock Chart & Stats

ILA 537.20ILA 0.00(0.00%)
At close:
ILA 525ILA 550ILA 575Sep 9Sep 28Oct 12Oct 26
Day’s Range
ILA 0.00 - ILA 0.00
52-Week Range
ILA 468.40 - ILA 600.00
Previous Close
ILA 537.20
Volume
N/A
Average Volume (3M)
92
Market Cap
ILS 128.82M
Enterprise Value
ILS 66.16M
Total Cash (Recent Filing)
ILS 16.22M
Total Debt (Recent Filing)
ILS 17.55M
Price to Earnings (P/E)
―
Beta
2.06
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-43.81
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And Gross Margin

Rapid revenue expansion combined with a gross margin near 59% indicates meaningful product demand and attractive underlying unit economics. If maintained, this gross-profit base can support continued investment in technology, capacity and commercialization while improving the company’s ability to scale toward profitability.

Strategic CDMO Commercialization

The first major CDMO manufacturing agreement expands BioHarvest beyond its consumer supplement base into potentially recurring, higher-value manufacturing revenue. A 20-ton commitment also provides commercial validation for its plant-cell platform, although meaningful contribution is expected only as production ramps from 2027.

Broader Partnership And Technology Pipeline

Progress across saffron and plant-based sweeteners demonstrates that the platform is being applied to multiple commercial opportunities rather than a single product. Ownership and royalty rights could provide longer-term participation in partner-led growth, while broader applications may strengthen BioHarvest’s strategic relevance.

Bears Say

Persistent Operating Losses

High gross margins have not yet translated into profitability, showing that operating expenses and commercialization investments remain too large for the current revenue base. Continued losses limit internally funded growth and leave execution dependent on achieving further scale, tighter spending and eventual improvement in operating leverage.

Ongoing Cash Burn

Negative operating and free cash flow means the business is still consuming cash to fund operations and investment rather than self-financing. Until sustained positive operating cash flow is reached, continued expansion may require use of cash reserves, financing capacity or other external funding sources.

Lowered 2026 Outlook And Weaker VINIA Profitability

The reduced consolidated outlook signals weaker near-term revenue visibility, while the shift from expected VINIA EBITDA profit to a loss indicates pressure in the company’s core consumer business. This raises the burden on future CDMO growth to offset slower D2C expansion and support the path to breakeven.

BioHarvest Sciences News

BHST FAQ

What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was ILA 468.40 and its highest was ILA 600.00 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is ₪128.82M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is today.
How were BioHarvest Sciences’s earnings last quarter?
BioHarvest Sciences released its earnings results on Aug 11, 2026. The company reported -ILA 53.973 earnings per share for the quarter, missing the consensus estimate of -ILA 37.463 by -ILA 16.509.
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -43.81.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
BioHarvest Sciences reported an EPS of -ILA 53.973 in its last earnings report, missing expectations of -ILA 37.463. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in IL:BHST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology